Avalon GloboCare Corp Dossier - Source-backed chat

Avalon GloboCare Corp

ALBTNASDAQ

SectorHealth Care

IndustryHealth Care Technology

Beta (adjusted)1.00

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.28Price as of 21 Jul 2026

Data confidenceNot applicable

Market Cap $3.7M

Enterprise Value $4.9M

Shares Outstanding 12.1M diluted

Moat Rating None

Next Earnings Date16 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Avalon GloboCare Corp. (ALBT) is undergoing a high-risk strategic pivot from legacy clinical laboratory services and cellular therapy toward consumer health (KetoAir breathalyzer) and generative AI software (the Catch-Up agentic AI video platform). While the company has regained temporary compliance with Nasdaq's stockholders' equity requirements, it faces severe liquidity constraints, including a working capital deficit of approximately $2.8 million as of March 31, 2026, and a net loss of $4.48 million for Q1 2026. With substantial doubt regarding its ability to continue as a going concern and heavy potential dilution from outstanding preferred stock and warrants, the stock presents an asymmetric downside risk for investors until commercial revenues materialize.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.0525%

The bear case assumes that Avalon fails to secure additional financing or that the commercial launch of its AI platform is delayed. Continued operating losses exhaust its remaining cash reserves, leading to a default on its outstanding promissory notes. Consequently, the company is forced to undergo severe dilutive conversions of its Series C, D, and E preferred shares, or faces delisting from Nasdaq and potential restructuring.

Base CaseCentral scenario

$0.3560%

In the base case, Avalon continues to experience high cash burn and relies on dilutive private placements and short-term debt to fund its operations. The commercialization of KetoAir and the Catch-Up AI platform progresses slowly, failing to generate sufficient near-term cash flow to offset operating losses. The company remains listed on Nasdaq but faces ongoing pressure on its stock price, necessitating a reverse stock split to maintain the minimum bid price requirement.

Bull CaseUpside scenario

$1.2515%

The bull case relies on rapid commercial adoption of the KetoAir breath ketone device in North America and the successful Q3 2026 launch of the Catch-Up autonomous agentic AI video platform in collaboration with Caylent and AWS. If these platforms generate immediate, high-margin SaaS and product revenues, Avalon could eliminate its going concern risk, achieve cash flow break-even, and leverage its newly compliant Nasdaq status to attract institutional investors.

Scenarios reflect our research view at the research date.

Key Investment Merits

Strategic collaboration with AWS Premier Tier partner Caylent to develop a fully autonomous agentic AI video platform.
FDA Class I registration renewal for the KetoAir breath ketone device, targeting the growing ketogenic health and wellness market.
Regained compliance with Nasdaq's minimum stockholders' equity requirement as of January 2026, preserving public market liquidity.

Key Investment Risks

Severe liquidity constraints with only $776,000 in cash as of March 31, 2026, and an active going concern warning from management and auditors.
Significant overhang and dilution risk from outstanding Series C, D, and E preferred stock, convertible notes, and warrants.
Unproven commercial track record in the highly competitive generative AI and consumer health technology sectors.

Thesis Invalidation Triggers

Securing a major non-dilutive licensing or distribution agreement for KetoAir that provides immediate cash inflows.
Failure to launch Phase 2 of the Catch-Up AI platform by the end of 2026.
Delisting notification from Nasdaq due to the stock price remaining below $1.00 for consecutive trading days.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.